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OBJECTIVE — Slowing of gastric emptying by hyperglycemia, a physiological response to
minimize postprandial hyperglycemia, may be impaired in patients with type 1 diabetes. The
causes and consequences on glucose homeostasis are unknown.
RESEARCH DESIGN AND METHODS — Consequences of euglycemia- and hyper-
glycemia-induced changes in gastric emptying on postprandial glucose ﬂuxes and excursions
werestudiedin10healthysubjectsand15type1diabeticsubjectsafteringestionofamixedmeal
using the double isotope approach ([6,6-
2H2] and [1-
13C]glucose) and scintigraphic measure-
ments of gastric emptying.
RESULTS — Gastric emptying was greater in type 1 diabetic subjects (90–120 min, P 
0.03),and50%retentiontimeswerecomparableinhealthysubjectsandtype1diabeticsubjects
(1678vs.15210,P0.32).Hyperglycemiamarkedlydelayedgastricemptyinginhealthy
subjects but did not alter it in type 1 diabetic subjects (50% retention time 222  18 vs. 167 
8 min, P  0.003 and 148  9 vs. 152  10 min, P  0.51). Plasma islet amyloid polypeptide
(IAPP) increased approximately fourfold in healthy subjects (P  0.001), whereas it was unde-
tectable in type 1 diabetic subjects. IAPP replacement, using the analog pramlintide, in type 1
diabetic subjects slowed gastric emptying to a comparable extent, as did hyperglycemia in
healthy subjects (P  0.14), and greatly reduced postprandial hyperglycemia (P  00.1). Meal-
derivedglucoseappearanceinplasma(10.70.5vs.6.80.7mol kg
1 min
1,P0.001)
was reduced, and splanchnic glucose sequestration increased (14.0  3.0 vs. 25.0  6.0%, P 
0.04).
CONCLUSIONS — In patients with type 1 diabetes the ability to delay gastric emptying in
response to hyperglycemia is impaired. This impairment contributes to exaggerated rates of
meal-derived glucose appearance and, ultimately, postprandial glucose excursions.
Diabetes Care 31:2325–2331, 2008
T
he importance of insulin and gluca-
gon in maintaining postprandial
glycemic excursions within a nar-
row range is well established (1). How-
ever, alterations in gastric emptying,
another potentially important factor (2),
are not generally considered to be of clin-
ical signiﬁcance for postprandial hyper-
glycemia in diabetes unless diabetes late
complications, such as gastroparesis,
have emerged (3,4).
Gastroparesis is a relatively rare dia-
betes late complication resulting from ir-
reversibleintestinalnervedamage(5)and
has to be distinguished from the physio-
logical inhibitory effects of acute hyper-
glycemia on gastric motility (6,7). The
latter has been proposed as a defense
mechanism to minimize postprandial hy-
perglycemia by reducing the rate of efﬂux
of glucose into the circulation from the
gut (8). This process may be of special
importance for patients with type 1 dia-
betes because they have been reported to
have a reduced ability to delay gastric
emptying in response to hyperglycemia
(9).
The pancreatic -cell hormone islet
amyloid polypeptide (IAPP) is cosecreted
with insulin in a ﬁxed molar ratio (10)
and reduces gastric emptying. Thus, pa-
tients with type 1 diabetes even without
concomitant enteric neuropathy should
have increased rather than delayed rates
ofgastricemptying,becausetheyareIAPP
deﬁcient (11). Accordingly, the present
studies were undertaken to test the hy-
pothesis that impairment in hyperglyce-
mia-induced delay in gastric emptying
should result in greater meal-derived glu-
cose appearance in the systemic circula-
tion and thus should contribute to
postprandial hyperglycemia in patients
with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— Written informed con-
sent was obtained from 10 healthy sub-
jects and 15 subjects with type 1 diabetes
after the Ludwig Maximilians University
ofMunichInstitutionalReviewBoardhad
approved the protocol. Healthy subjects
(seven men and three women, 39  4
years of age, body weight 80  4 kg) had
normal routine laboratory blood test re-
sults as well as no family history of diabe-
tes and had normal glucose tolerance
(assessed by oral glucose tolerance tests
according to World Health Organization
criteria [12]). Healthy subjects and type 1
diabetic subjects (eight men and seven
women, 37  2 years of age, body weight
763kg)hadnormalphysicalexamina-
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No type 1 diabetic subject had symptoms
of cardiac autonomic or peripheral sen-
sory neuropathy assessed by electrocar-
diogram breath-dependent variability
and clinical examination of peripheral
sensory function. None had symptoms or
a history of gastrointestinal neuropathy
(i.e., bloating, vomiting, constipation, di-
arrhea, or redundant postprandial hypo-
glycemia) or evidence for nephropathy,
assessed by microalbumin excretion. Ret-
inal fundus photography showed only
mild background retinopathy in three
type 1 diabetic subjects. All type 1 dia-
betic subjects had been receiving contin-
uous subcutaneous insulin infusion
therapy for at least 3 months before the
study with good glycemic control as as-
sessed by A1C (7.3  0.2%) and seven-
point self-obtained blood glucose proﬁles
without severe hypoglycemic episodes.
Three days before the study, all subjects
had been consuming a weight-maintain-
ing diet containing at least 200 g of car-
bohydrates and had abstained from
alcohol, smoking, and exercise.
Protocol
Healthy subjects were studied on two oc-
casions (euglycemia and hyperglycemia),
and type 1 diabetic subjects were studied
on three occasions (euglycemia and hy-
perglycemia with and without 30 g
pramlintide [Amylin Pharmaceuticals,
San Diego, CA], injected subcutaneously
in the lower abdominal wall with the
meal, which was designed to replace ab-
sent IAPP secretion as indicated by its ef-
fects on gastric emptying compared with
hyperglycemia in healthy subjects esti-
mated from previous studies [13,14]).
Healthy subjects received only placebo
injections. Experiments were separated
by at least 1 day and undertaken in a ran-
domized, single-blinded order. Subjects
refrained from food intake at least 10 h
before admission to the clinical research
unit between 7:00 and 7:30 A.M.o nt h e
study day. A dorsal hand vein was cannu-
lated, and temperature was maintained at
40°C with a thermoregulated lamp for ar-
terialized venous blood sampling (8). On
the nights before the study days, type 1
diabetic subjects were instructed to mea-
sure plasma glucose concentrations at 10
P.M. and 2 A.M. to adjust basal insulin in-
fusionwiththeaimofaverageplasmaglu-
cose concentrations of 5 or 10 mmol/l,
respectively (15). After admission to the
clinicalresearchunit,thecontinuoussub-
cutaneousinsulininfusionwasdiscontin-
ued, and an intravenous insulin infusion
wasadjustedaccordinglytomaintainpre-
prandialplasmaglucoseconcentrationsat
5 and 11 mmol/l, respectively.
Postprandial intravenous insulin in-
fusion rates were based on the individual
bolus requirements from the subcutane-
ous pump therapy. Postprandial insulin
infusion rates of euglycemic and hyper-
glycemic experiments were 6.4  0.9,
6.8  0.8, 3.5  0.8, 1.4  0.3, and
0.90.1isletequivalents/hat0–30,35–
60, 65–120, 125–240, and 240–330
min, respectively.
At 8 A.M., a primed (25 mol) contin-
uous (0.25 mol   kg
1   min
1) infu-
sion of [1-
13C] glucose was started via a
forearm vein for measurements of plasma
glucose turnover in all except the hyper-
glycemicexperimentsofhealthysubjects.
At least 3 h were allowed for achievement
of isotope equilibration. Before meal in-
gestion, three baseline blood samples
werecollectedforfastingglucose,insulin,
glucagon, and IAPP concentrations and
[1-
13C]glucose enrichments. Thereafter,
subjects ingested a standardized meal
within 5 min. The meal (450 kcal, 45%
carbohydrates, 30% fat, and 25%
protein) consisted of three scrambled
eggs and 100 ml jelly containing 50 g of
glucose enriched with 3 g 6,6-dideutero-
glucose. Consumption of 200 ml spar-
kling water was allowed with the meal.
Subjects remained in a semisupine posi-
tion throughout the study period. Over
the initial 90 min of the postprandial pe-
riod, blood samples were taken at 15-min
intervals and thereafter at 30-min inter-
valsuntilcompletionoftheexperimentat
330 min except for the hyperglycemic ex-
perimentsinhealthysubjects,whichwere
terminated at 240 min. The scrambled
eggs and jelly were additionally labeled
with
99mTc-Sn-colloid (70 MBq) for
measurements of gastric emptying by
high-resolution scintigraphy (20 images/
min; Orbiter, Siemens, Erlangen, Ger-
many), starting immediately after food
ingestion for the remainder of the
experiment.
After the hyperglycemic experiments
in type 1 diabetic subjects had been com-
pleted, we performed hyperglycemic ex-
periments in healthy subjects isoglycemic
to those of the hyperglycemic placebo ex-
periments of type 1 diabetic subjects us-
ing a glucose infusion algorithm as
described previously (16,17). Fasting
plasma glucose was clamped at 11.03 
0.1 mmol/l, not signiﬁcantly different
from preprandial plasma glucose concen-
trations in type 1 diabetic subjects. Glu-
cose infusion rates in hyperglycemic
isoglycemic experiments in healthy sub-
jectswerestarted2.5hbeforemealinges-
tion. No insulin was infused in healthy
subjects. Mean glucose infusion rates be-
fore meal ingestion were 49.1 8.4 mol  
kg
1 min
1afteranintravenousbolusof
16.2  2.2 g glucose. Postprandial rates
of glucose infusion in healthy subjects
were adjusted to produce postprandial
plasma glucose excursions not signiﬁ-
cantly different from those in hyperglyce-
mic experiments in type 1 diabetic
subjects. Mean postprandial rates of glu-
cose infusion were 96.5  9.8 mol  
kg
1   min
1. The hyperglycemic exper-
iments in healthy subjects were termi-
nated 4 h after meal ingestion. In type 1
diabetic subjects, no glucose was infused
inthepostprandialstate.Healthysubjects
servedinpartasacontrolgroupinstudies
in which effects of pramlintide adminis-
tration on postprandial glucose ﬂuxes in
14 healthy subjects are reported (8).
Analytical procedures
Gastric outlines on the maximum-inten-
sity image were deﬁned as the region of
interest. Completion of gastric emptying
was assumed at a reduction of the initial
activity to 5%. Loss of activity was cor-
rected for the radioactive half-life of
99mTc (8).
Blood samples were collected for
plasma glucose concentrations and
[1-
13C]- and [6,6-
2H2]glucose enrich-
ments in oxalate-ﬂuoride tubes and for
plasma insulin, glucagon, and IAPP con-
centrations in EDTA tubes containing a
proteaseinhibitor.Sampleswereimmedi-
ately placed on ice, and plasma was sepa-
rated within 30 min by centrifugation at
4°C. Plasma glucose concentrations and
[1-
13C]- and [6,6-
2H2]glucose enrich-
ments were measured as described previ-
ously (8). Plasma insulin and glucagon
concentrations were determined by stan-
dard radioimmunoassay (8), and IAPP
concentrations were determined using an
enzyme-linked immunosorbent assay
(Linco Research).
Calculations
Systemic release and uptake of glucose
were calculated with steady-state equa-
tions before meal ingestion and subse-
quently with the non–steady-state
equationsofDeBodoetal.(8)usingapool
fraction of 0.65 and a volume of distribu-
tion of 200 ml/kg. Rates of appearance of
the oral glucose load in the systemic cir-
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2H2]glucose enrichments using the
equation of Chiasson et al. (8). The en-
dogenous glucose release was calculated
as the difference between the overall rate
ofplasmaglucoseappearanceandtherate
of appearance of exogenous glucose (8).
Splanchnic glucose disposal of the in-
gested glucose load was calculated as the
difference between the amount of glucose
emptied by the stomach and the amount
of glucose that appeared in the systemic
circulation at the end of the experiments.
Statistical analysis
Data are means  SEM unless otherwise
speciﬁed using Statistica statistical soft-
ware (1998 edition; Statsoft, Tulsa, OK).
Normality of the distribution was as-
sessed using the Kolmogorov-Smirnov
test. Comparisons between the groups
and baseline with postprandial values
were performed using ANOVA for exclu-
sion of carryover effects followed by post
hoc comparison with paired and un-
paired t tests within and between patient
groups, respectively. P  0.05 was con-
sidered statistically signiﬁcant. Correla-
tion between variables was performed
using Spearman’s regression analysis.
RESULTS
Gastric retention, lag period, 50%
retention time, 60-min retention
Initialratesofgastricemptyingduringeu-
glycemia were greater in type 1 diabetic
subjects, with signiﬁcantly greater rates
between 90 and 120 min (all P  0.03).
However, lag periods, 60-min retention,
and 50% retention times (T50) were not
statistically different in healthy subjects
and type 1 diabetic subjects (all P  0.3)
(Fig. 1). Hyperglycemia markedly slowed
gastric emptying in healthy subjects with
greaterlagperiods,60-minretention,and
T50 (all P  0.001), with the most pro-
nounced effects occurring within the ﬁrst
60 min after meal ingestion. In contrast,
hyperglycemiahadnoeffectsonthesepa-
rameters in type 1 diabetic subjects.
Pramlintide administration markedly
delayed gastric emptying in type 1 dia-
betic subjects (lag period, 60-min reten-
tion, and T50, all P  0.001) compared
with placebo, with the most pronounced
effects occurring within the initial 60 min
after meal ingestion. As a consequence,
lag period, 60-min retention time, and
T50 were restored to values comparable
to those observed in hyperglycemic ex-
periments in healthy subjects (P  0.29,
0.06, and 0.29, respectively).
Plasma glucose and correlation
between peak plasma glucose at 60
min and gastric content at 45 min
Fasting plasma glucose concentrations in
the euglycemic experiments were slightly
but signiﬁcantly greater in type 1 diabetic
subjects (area under the curve [AUC]
60 to 0 min: 265  7 vs. 334  13
mmol l
1 min
1,P0.001);however,
after meal ingestion plasma glucose in-
creasedcomparablyintype1diabeticand
healthy subjects (increase in AUC 0 to 60
min: 131  15 vs. 162  20 mmol   l
1  
min
1, P  0.45) (Fig. 2). In the hyper-
glycemic experiments, fasting and post-
prandial glucose concentrations did not
differbetweenhealthysubjectsandtype1
diabetic subjects in the placebo experi-
ments (AUC 60 to 0 min and 0–330
min:6654vs.6869and2,95945
vs. 2,915  80 mmol   l
1   min
1, P 
0.08 and 0.69, respectively).
Pramlintide administration com-
pletely prevented any increase in post-
prandial plasma glucose above baseline
during the entire postprandial period so
that mean plasma glucose concentrations
were reduced by 3 mmol/l (P  0.001).
The AUCs for 0–330 min were 3,739 
123 vs. 2,995  86 mmol   l
1   min
1
Figure 1—Percent gastric retention versus minutes (A), percent gastric retention, lag periods,
50%retentiontime,percentretentionat60min(B),andinversecorrelationofgastricretentionat
45 min and incremental plasma glucose concentrations at 60 min (C) in all placebo experiments.
blue, healthy subjects, euglycemia, placebo, n  10; green, healthy subjects, hyperglycemia,
placebo (isoglycemic to hyperglycemia placebo in type 1 diabetic patients), n  10; yellow, type
1 diabetic patients, euglycemia, placebo, n  15; red, type 1 diabetic patients, hyperglycemia,
placebo,n15;gray,type1diabeticpatients,hyperglycemia,pramlintide(30g),n15.Note
that initial gastric emptying was greater in type 1 diabetic patients (P  0.03). Hyperglycemia
delayedgastricemptyinginhealthysubjects(P0.001)withouteffectsintype1diabeticpatients
(n.s.). In type 1 diabetic patients, pramlintide reduced gastric emptying (P  0.001) compared
withplacebobutnotsigniﬁcantlydifferentfromgastricemptyingunderhyperglycemicconditions
in healthy subjects. Comparison was made using paired and unpaired t tests within and between
patient groups.
Woerle and Associates
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plasma glucose concentrations at 60 min
correlated with gastric content at 45 min
(r  0.52, P  0.001) (Fig. 1).
Plasma insulin, glucagon, and IAPP
Plasma insulin concentrations paralleled
those of plasma glucose concentrations in
healthy subjects and were on average
11-fold greater in the hyperglycemic
than in the euglycemic experiments.
AUCsovertheentireexperimentalperiod
were 52,838  3,975 versus 606,929 
Figure 2—Plasma glucose concentrations, plasma insulin, glucagon, and IAPP concentrations, and rates of exogenous (meal) and endogenous
plasma glucose appearance. yellow circles, type 1 diabetic patients (T1DM), euglycemia, placebo, n  15; red squares, type 1 diabetic patients,
hyperglycemia,placebo,n15;graydiamonds,type1diabeticpatients,hyperglycemia,pramlintide(30g),n15;bluecircles,healthysubjects,
euglycemia, placebo, n  10; green squares, healthy subjects, hyperglycemia, placebo (isoglycemic to hyperglycemia placebo in type 1 diabetic
patients), n  10. Note that subcutaneous pramlintide reduced postprandial glucose in type 1 diabetic patients (P  0.001). Plasma insulin in type
1 diabetic patients was not different (n.s.). Matching isoglycemic hyperglycemia in healthy subjects resulted in greater insulin concentrations (P 
0.001). Plasma IAPP increased as a response to hyperglycemia in healthy subjects (P  0.001) with no detectable IAPP concentrations under
euglycemiaandhyperglycemiaintype1diabeticpatients(n.s.).Pramlintidereducedglucagonfrom0to90minintype1diabeticpatients(P0.01).
Endogenous glucose production was greater in type 1 diabetic patients (P  0.001); pramlintide showed no effect (n.s.). Exogenous glucose was
greater in type 1 diabetic patients (P  0.005) compared with healthy subjects and was reduced when pramlintide was given (P  0.001).
Comparison was made using paired and unpaired t tests within and between patient groups.
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1   min
1 (P  0.001).
Intype1diabeticsubjects,plasmainsulin
concentrationswerecomparableinallex-
periments (AUCs over the entire experi-
mental period: 114,146  9,344,
113,55110,157,and114,7787,514
pmol   l
1   min
1, all P  0.70) but on
average approximately twofold greater
than those for healthy subjects (P 
0.001) (Fig. 2).
Plasma glucagon concentrations de-
creased signiﬁcantly after meal ingestion
inhealthysubjects(AUC60to0minvs.
0–60 min: 3,574  279 vs. 3,283  294
pg   ml
1   min
1, P  0.01) but not in
type 1 diabetic subjects (AUC 60 to 0
min vs. 0–60 min: 2,433  196 vs.
2,597203pg ml
1 min
1,P0.16)
(Fig. 2). When pramlintide was given in
type 1 diabetic subjects, plasma glucagon
concentrations decreased to a nadir at 60
min and were signiﬁcantly lower within
theﬁrst90min(AUC0–90min:3,829
280 vs. 3,085  289 pg   ml
1   min
1,
placebo versus pramlintide, P  0.01).
In euglycemic experiments in healthy
subjects, plasma IAPP concentrations in-
creased from 2.1  0.6 pmol/l to peak
values of 12.4  1.3 pmol/l at 90 min,
averaging 8.8  0.9 pmol/l postprandi-
ally. In the hyperglycemic experiments,
plasma IAPP concentrations were signiﬁ-
cantly greater before meal ingestion (on
average18.94.2pmol/l,AUC30to0
min: 63  17 vs. 566  126 pmol   l
1  
min
1, P  0.001) and increased to an
average of 42.8  7.3 pmol/l (AUC
0240 min: 2,104  206 vs. 10261 
1,746 pmol   l
1   min
1, P  0.0001)
(Fig. 2). In type 1 diabetic subjects,
plasma IAPP was undetectable under eu-
glycemic and hyperglycemic conditions
both pre- and postprandially.
Rates of exogenous (meal) and
endogenous plasma glucose
appearance
In type 1 diabetic subjects, preprandial
endogenous glucose production was sig-
niﬁcantly greater in both the euglycemic
and hyperglycemic experiments than that
in healthy subjects (AUC 60 to 0 min:
545  21 mol/kg in healthy subjects vs.
788  41, 963  38, and 911  65
mol/kg,respectively,intheexperiments
with type 1 diabetic subjects, all P 
0.001).
In healthy subjects, postprandial en-
dogenous glucose production was sup-
pressed by 60.6  1.5%. In type 1
diabetic subjects, the degree of suppres-
sion was comparable in the euglycemic
and hyperglycemic experiments (45.4 
2.5 and 45.1  1.6%, respectively, P 
0.50) and lower than that in healthy sub-
jects (both P  0.001). Postprandial en-
dogenous glucose production did not
differ after placebo and pramlintide ad-
ministration in type 1 diabetic subjects
(AUC 0–330 min: 2,991  154 vs.
2,773199mol/kg,P0.21)(Fig.2).
Rates of exogenous glucose appear-
ance (meal-derived glucose) increased
from 30 to 90 min in type 1 diabetic sub-
jects compared with those of healthy sub-
jects in the euglycemic placebo
experiments (AUC 30–90 min: 743  47
vs. 1,012  67 mol/kg, P  0.005) and
were unaffected by hyperglycemia (AUC
30–90 min in the hyperglycemic placebo
experiment: 1,054  50 mol/kg, P 
0.80 compared with placebo euglycemia
in type 1 diabetes). Administration of
pramlintide signiﬁcantly reduced rates of
exogenous glucose appearance in type 1
diabeticsubjectsfrom15to90min(AUC
15–90 min: 1,220  58 vs. 269  47
mol/kg,P0.001)withslightlybutsig-
niﬁcantly greater rates for the remainder
of the experiment. Overall, they were not
signiﬁcantly different from those of
healthy subjects during euglycemia (AUC
0–330 min in healthy subjects and type 1
diabeticsubjectsafterpramlintideadmin-
istration, respectively: 2,750  144
vs. 2,251  241 mol/kg, P  0.145)
(Fig. 2).
CONCLUSIONS— Majorﬁndingsof
these studies are that the physiological
defense mechanism to delay gastric emp-
tying in response to postprandial hyper-
glycemia is impaired in patients with type
1diabetes.Moreover,ourstudiesdemon-
strate that this impairment leads to exag-
gerated rates of meal-derived glucose
appearance in plasma and thus contrib-
utes to postprandial hyperglycemia. IAPP
increased markedly in healthy subjects
and was associated with a profound delay
in gastric emptying. A delay in gastric
emptying in type 1 diabetic patients com-
parable to that found in healthy subjects
markedly improved postprandial glucose
excursionsintype1diabeticpatients.De-
layed gastric emptying decreased pro-
foundly initial appearance of meal-
derived glucose in the systemic
circulation in conjunction with increased
splanchnic glucose sequestration.
These ﬁndings appear at ﬁrst glance
to contradict those of previously pub-
lishedstudiesreportingthatphysiological
hyperglycemia delays gastric emptying in
patientswithtype1diabetes(9).Asinour
studies, gastric emptying was not found
to be delayed in patients with type 1 dia-
betes under euglycemic conditions, but a
blunted responsiveness to hyperglycemia
was reported with a 50% reduction in
the delay of gastric emptying in patients
with type 1 diabetes. These ﬁndings and
the results of the present studies support
theconceptthatthephysiologicaldefense
mechanism to delay gastric emptying in
response to postprandial hyperglycemia
is impaired in patients with type 1 diabe-
tes. The complete unresponsivness to hy-
perglycemia in our studies may be
explained by different study designs. In
ourstudiestypicalpostprandialhypergly-
cemic glucose ﬂuctuations were allowed,
whereas Schvarcz et al. (9) used the con-
tinuous hyperglycemic clamp technique.
Undereuglycemicconditions,plasma
IAPP concentrations paralleled those of
insulin concentrations in healthy sub-
jects. When exposed to hyperglycemia,
IAPP concentrations increased from 9
to 43 pmol/l postprandially. No apparent
IAPP secretion could be detected either
under euglycemic or hyperglycemic con-
ditions in patients with type 1 diabetes.
Pramlintide administration in type 1 dia-
betic patients delayed gastric emptying to
an extent comparable to that with hyper-
glycemia in healthy subjects. This result,
however, does not necessarily imply
concentrations comparable to those of
endogenous IAPP found in healthy sub-
jects but rather a comparable pharmaco-
dynamic effect on gastric emptying.
Taking this into consideration, IAPP deﬁ-
ciency may be seen as one cause for the
unresponsiveness in delaying gastric
emptying. To prove that IAPP deﬁciency
wasthesolereasonforthelackofdelayin
gastric emptying, direct inhibition of the
IAPP effects using a speciﬁc antagonist
would be required. Such an antagonist,
however, is not available for human use,
buttheviewthatIAPPdeﬁciencyplaysan
important role in the lack of delay in gas-
tric emptying in response to hyperglyce-
mia is further supported by the highly
potent inhibitory effects of IAPP on gas-
tric emptying (18).
Instudiessuggestingthatinsulinmay
be another important regulator of gastric
emptying in healthy volunteers (19), the
effects of hyperinsulinemia on gastric
emptyingwerefoundtobemarginal(19).
Interestingly,instudiesundertakeninpa-
tients with type 1 diabetes, no effect of
insulin on gastric emptying was detected
(20). Gastric emptying was found to be
Woerle and Associates
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under euglycemic conditions in our stud-
ies even though plasma insulin concen-
trations were signiﬁcantly higher
compared with those of healthy volun-
teers. This result also argues against an
importanteffectofinsulinongastricemp-
tying in patients with type 1 diabetes.
Gastric emptying is modulated by
feedbackmechanismsarisingfromthein-
teractionofnutrientswiththesmallintes-
tine (21). Both intestinal vagus nerve
activity and intestinal peptides regulate
gastric emptying. Glucagon-like peptide
1 (GLP-1) inhibits gastric emptying (22).
Its secretion, however, is stimulated by
the intestinal nutrient content and ﬂow
ratherthanbytheplasmaglucoseconcen-
tration itself (23). Furthermore, the fact
that gastric emptying and thus nutrient
ﬂowtotheintestine,whichshouldreduce
direct intestinal L-cell–stimulated and
also cholinergic GLP-1 secretion, was de-
layed in the hyperglycemic experiments
in healthy subjects speaks against a major
role of GLP-1 as a mediator of hypergly-
cemia-induced delay in gastric emptying.
Direct inhibition of vagal nerve activ-
ity induced by hyperglycemia could be
another important factor to delay gastric
emptying. To our knowledge there is no
convincing evidence that hyperglycemia
per se as applied in our studies affects va-
gal activity. Interestingly, in healthy hu-
manshyperglycemiahasbeenreportedto
cause profound inhibition of vagal activ-
ity accompanied by substantial IAPP se-
cretion (24). In contrast, however, in
IAPP-deﬁcientpatientswithtype1diabe-
tes, hyperglycemia did not affect vagal ac-
tivity (9). Because the inhibitory effect of
IAPPongastricemptyingseemstobeme-
diated via inhibition in vagal nerve activ-
ity (24), our experiments are consistent
with the concept that the hyperglycemia-
induced delay in gastric emptying may be
at least partially regulated via an IAPP-
mediated inhibitory effect on vagal nerve
activity.
Recent studies showed that IAPP and
pramlintide suppress postprandial gluca-
gon secretion (25,26). Indeed, we found
greater suppression of postprandial glu-
cagon in type 1 diabetic patients when
pramlintide was given. This suppression
may have occurred either directly by an
inhibitory effect of pramlintide on the
pancreatic	-cellorindirectlyviareduced
efﬂux of nutrients from the gut, because
aminoacidssuchasarginineareknownto
stimulate glucagon secretion (27). Thus,
it remains unclear whether the greater
suppression of glucagon secretion is at-
tributabletoadirectinhibitionofthepan-
creatic 	-cells or to reduced inﬂux of
nutrients from the gut. However, because
endogenous glucose production was
comparable in the placebo and pramlint-
ide experiments in type 1 diabetic pa-
tients, we believe that the pramlintide-
induced reduction of postprandial
glucose concentrations was primarily due
to the delay in gastric emptying.
Ratesofmeal-derivedglucoseappear-
anceweresigniﬁcantlygreaterintheearly
postprandial period in type 1 diabetic
subjects when placebo was given and
would correspond to a 30% reduction
in splanchnic glucose sequestration. If we
assume that all of this glucose had been
used for glycogen formation, our esti-
mates are in close agreement with nuclear
magneticresonancespectroscopicstudies
revealing a 30% reduction in glycogen
content in moderately hyperglycemic pa-
tients with type 1 diabetes (28). Interest-
ingly, in the pramlintide experiments a
nearlyidenticalproportionofhepaticglu-
cose sequestration was found in patients
with type 1 diabetes compared with our
healthy subjects. This result could have
been related to the greater suppression of
postprandial glucagon secretion or ini-
tially reduced inﬂux of glucose from the
gut and more efﬁcient uptake by the liver
or increased rates of glycolysis in the gut.
Teleologically, the slowing of gastric
emptying during hyperglycemia can be
seen as an important defense mechanism
to prevent hyperglycemia. IAPP secretion
is linked to insulin release (10). As a re-
sponse to hyperglycemia, the pancreatic
-cellwithitsglucosesensorincreasesin-
sulin and IAPP secretion. Insulin sup-
presses hepatic glucose output and
increases peripheral glucose uptake (17).
IAPP reduces the release of nutrition
from the gut and thus reduces the efﬂux
of glucose into the system and thereby
prevents aggravation of postprandial
hyperglycemia.
Taken together, these studies high-
light the importance of a delay in gastric
emptying as a response to hyperglycemia
to minimize postprandial glucose excur-
sions, a defense mechanism not operative
in patients with type 1 diabetes, which
maybeexplainedatleastpartiallybyIAPP
deﬁciency.
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